Video summary

Endocrinology - Diabetes Mellitus : Types | Medicine | Read Harrison's Series with Dr. Santhosh

Main summary

Key takeaways

Educational

Main ideas / lessons

  • Diabetes mellitus is a group of metabolic disorders that share a common outcome: hyperglycemia (even though the underlying causes/pathophysiology can differ).
  • Diagnosis is standardized using ADA guidelines (the speaker references ADA 2025), using thresholds based on:
    • fasting plasma glucose
    • 2-hour postprandial glucose
    • HbA1c
    • or random plasma glucose with symptoms
  • The lecture is organized across multiple sessions; today focuses on:
    1. What diabetes mellitus is
    2. Diagnosis + classification
    3. Core physiology of glucose regulation
    4. Overview of major diabetes types (especially Type 1, Type 2, LADA/Type 1.5, and MODY)
  • Why tight glucose regulation matters: chronic hyperglycemia increases risk of complications, grouped into:
    • Microvascular: retinopathy, nephropathy, neuropathy
    • Macrovascular: stroke, coronary artery disease, peripheral vascular disease
  • Glucose physiology (fed vs starved + hormone roles):
    • Insulin lowers blood glucose (fed state), promoting glycogen storage and fat synthesis
    • Glucagon raises blood glucose (starved state), promoting glycogen breakdown and gluconeogenesis
    • Insulin secretion has:
      • basal (constant) secretion when glucose is above ~70 mg/dL
      • meal-stimulated spikes after carbohydrate intake
    • Diabetes treatments aim to mimic physiology (basal long-acting + meal-related short-acting insulin)

Detailed diagnostic methodology / criteria (ADA-based)

A) Diagnose diabetes mellitus if ANY of the following are met

  • Fasting Plasma Glucose (FPG)

    • Diabetes: ≥ 126 mg/dL
    • Normal: 70–100 mg/dL
    • Pre-diabetes (Impaired Fasting Glucose, IFG): 101–125 mg/dL

  • HbA1c

    • Diabetes: ≥ 6.5%
    • Pre-diabetes: 5.7–6.4%
    • Normal: ≤ 5.6%

  • 2-hour Postprandial Plasma Glucose (after meal/OGTT standardization)

    • Diabetes: ≥ 200 mg/dL
    • Pre-diabetes: 141–199 mg/dL
    • Labeling used in the talk:
      • Impaired glucose tolerance for the above pre-diabetes post-meal range

  • Random Blood Glucose (RBS / random plasma glucose)

    • Diabetes can be diagnosed using random glucose only if:
      • RBS ≥ 200 mg/dL
      • AND symptoms of diabetes are present
    • Symptoms referenced (3 Ps + weight loss):
      • Polyuria
      • Polydipsia
      • Polyphagia
      • Weight loss (added as a 4th symptom)

B) What about “fasting”?

  • Fasting definition: no calorie intake for ≥ 8 hours
  • Water is allowed (non-caloric fluids).
  • Fasting can be done day or night as long as it meets the 8-hour no-calorie requirement.

C) Special note on postprandial testing standardization

  • 2-hour postprandial glucose depends on meal carbohydrate content (e.g., sweets vs low glycemic meal).
  • Therefore, standard testing (not just any meal) is emphasized.
  • Oral Glucose Tolerance Test (OGTT) reference for gestational diabetes:
    • Measure 2-hour post-load plasma glucose after 75 g anhydrous glucose dissolved in water.

D) Gestational diabetes note (OGTT-based concept)

  • Post-load glucose is measured 2 hours after the standardized 75 g glucose intake.

Classification of diabetes mellitus (ADA categories referenced)

The speaker states ADA divides diabetes into four major categories:

  • Type 1
  • Type 2
  • Gestational diabetes mellitus (GDM)
  • Other specific types (including monogenic forms, pancreatic disease, drug-induced, etc.)

“Other specific types” examples listed

  • Monogenic diabetes (e.g., MODY)
  • Diabetes due to pancreatic disease (chronic pancreatitis, fibrocalculus pancreatitis, pancreatic cancer)
  • Drug-induced diabetes, with examples:
    • Glucocorticoids
    • Immunosuppressants like cyclosporine and tacrolimus

Core physiology applied to treatment idea (insulin mimicry)

  • Basal insulin production: continuous small secretion to ensure glucose utilization (glucose transporters like GLUT4 depend on insulin).
  • Meal-stimulated insulin spikes: rise after meals and fall after glucose normalizes.
  • Treatment goal for insulin users:
    • provide long-acting insulin for basal needs
    • short-acting insulin for meal spikes

Type 1 vs Type 2 (comparative framework)

Type 1 diabetes mellitus (absolute insulin deficiency)

  • Main defect: beta-cell destruction → absolute insulin deficiency
  • Underlying cause: mostly autoimmune
    • >95% have autoantibodies (Type 1A)
    • ~5% without detectable antibodies (idiopathic / Type 1B)
  • Key lab implication:
    • C-peptide: low or undetectable
  • Antibodies:
    • Autoantibodies target beta-cell proteins/related antigens (examples listed below)
  • Natural history described as stages:
    • Stage 1: antibodies positive, normal blood glucose
    • Stage 2: declining beta-cell mass → impaired regulation (“dysglycemia”)
    • Stage 3: overt diabetes when beta-cell mass falls below critical level
  • Clinical tendency emphasized: high risk of ketosis / DKA due to near/absolute insulin lack

Type 2 diabetes mellitus (insulin resistance first)

  • Main defect: insulin resistance
  • Insulin level early: normal or high (hyperinsulinemia) as compensation
  • C-peptide: normal or high initially
  • Antibodies: typically negative
  • Signs of insulin resistance referenced:
    • Acanthosis nigricans
    • Skin tags
  • Insulin dependence: tends to be late, not required at diagnosis in many cases
  • Ketosis: generally less prone theoretically (because some insulin exists), but speaker notes Indians may still develop ketosis.

LADA / “Type 1.5” (latent autoimmune diabetes of adults)

  • Why “1.5”: shares features of both Type 1 and Type 2.
  • Shared with Type 1:
    • autoantibodies positive
  • Shared with Type 2:
    • adult onset (>25 years)
    • insulin dependence is not immediate (at first)
  • LADA ADA-style diagnostic criteria (as stated):
    • Age of onset > 25 years
    • At least one autoantibody positive (from Type 1 antibody list)
    • No insulin requirement for at least 6 months after diagnosis
  • Overall interpretation in the talk: slow autoimmune destruction; manifests like Type 2 initially, later behaves more like Type 1.

MODY (Maturity Onset Diabetes of the Young) — monogenic diabetes

  • Category: monogenic (single-gene defect)
  • Mechanism emphasized:
    • No insulin resistance
    • No autoantibody-mediated beta destruction
    • Problem is impaired glucose sensing and/or impaired insulin secretion despite normal beta-cell number
  • Inheritance:
    • Autosomal dominant
    • Family history is needed for diagnosis (vertical transmission)

“Table” rules / high-yield MODY facts (as provided)

  • 14 types exist, but 6 are more common and commonly tested.

HNF-related MODY (odd numbers) mapping

  • MODY1, MODY3, MODY5 are due to HNF mutations
    • HNF4α → MODY1
    • HNF1α → MODY3
    • HNF1β → MODY5 (as stated by speaker; note: also commonly tested)

Other MODY gene examples mentioned

  • Glucokinase mutation → MODY2
    • glucose → ATP step impaired; defective triggering of insulin release
  • IPF-1 mutation → MODY4
  • NeuroD1 mutation → MODY6

Most common MODY facts (as stated)

  • Most common: MODY3 (first >50% claim)
  • MODY2 is second (~>1/3 claim)

MCQ-style associations mentioned

  • Exaggerated response to sulfonylureas: MODY3
  • Renal cysts / resembles ADPKD: MODY5 (HNF1β mutation)

Speaker / sources featured

  • Dr. Santhosh (primary instructor, referenced as “Dr. Santhosh” throughout the title and spoken address)
  • ADA (American Diabetes Association) guidelines, specifically referenced as “ADA 2025”
  • Harrison’s (textbook referenced: “Read Harrison’s Series” and graphs mentioned from Harrison)

No other named speakers, interviewees, or distinct sources are clearly identified beyond these.

Original video